Charles River Laboratories International, Inc.
CRL
$144.70
$3.502.48%
NYSE
| 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 111.87% | -407.93% | -25.96% | 39.73% | -64.01% |
| Total Depreciation and Amortization | -8.46% | 5.11% | 2.46% | 0.85% | 6.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -81.43% | 1,341.46% | -9.14% | -2.33% | 129.74% |
| Change in Net Operating Assets | 103.04% | -159.30% | 730.88% | 76.44% | -225.28% |
| Cash from Operations | 7.74% | -36.71% | 30.10% | 49.00% | -41.21% |
| Capital Expenditure | 21.55% | -95.28% | 1.94% | 50.11% | -1.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -636.89% | -102.81% | 202.93% | -154.23% | 56.91% |
| Cash from Investing | 40.24% | -256.89% | 65.53% | 27.89% | 64.01% |
| Total Debt Issued | 297.28% | -55.52% | -46.50% | 46.34% | -32.13% |
| Total Debt Repaid | 15.49% | 46.37% | 52.56% | -137.57% | 8.82% |
| Issuance of Common Stock | -- | -1.41% | -5.69% | -96.16% | 262.10% |
| Repurchase of Common Stock | -284,683.87% | 99.88% | -1,030.65% | 4.67% | -6,627.34% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -321.40% | 66.27% | 42.02% | -951.90% | 53.85% |
| Cash from Financing | -38.81% | 63.44% | 27.40% | -1,658.15% | -85.15% |
| Foreign Exchange rate Adjustments | 139.15% | -274.57% | 330.52% | 60.15% | -165.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 530.94% | -119.81% | 119.45% | -391.43% | -54.52% |